331 related articles for article (PubMed ID: 29370839)
1. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
Ricciardi GRR; Russo A; Franchina T; Schifano S; Mastroeni G; Santacaterina A; Adamo V
BMC Cancer; 2018 Jan; 18(1):97. PubMed ID: 29370839
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Jacot W; Pons E; Frenel JS; Guiu S; Levy C; Heudel PE; Bachelot T; D'Hondt V; Darlix A; Firmin N; Romieu G; Thezenas S; Dalenc F
Breast Cancer Res Treat; 2016 Jun; 157(2):307-318. PubMed ID: 27167986
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
6. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V; Ferraro GB; Kodack DP; Badeaux M; Shankaraiah RC; Seano G; Kloepper J; Vardam T; Martin JD; Naxerova K; Bezwada D; Qi X; Selig MK; Brachtel E; Duda DG; Huang P; Fukumura D; Engelman JA; Jain RK
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26547932
[TBL] [Abstract][Full Text] [Related]
8. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
[TBL] [Abstract][Full Text] [Related]
9. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Jain S; Shah AN; Santa-Maria CA; Siziopikou K; Rademaker A; Helenowski I; Cristofanilli M; Gradishar WJ
Breast Cancer Res Treat; 2018 Sep; 171(2):371-381. PubMed ID: 29850984
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
Montemurro F; Delaloge S; Barrios CH; Wuerstlein R; Anton A; Brain E; Hatschek T; Kelly CM; Peña-Murillo C; Yilmaz M; Donica M; Ellis P
Ann Oncol; 2020 Oct; 31(10):1350-1358. PubMed ID: 32634611
[TBL] [Abstract][Full Text] [Related]
15. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
Lu D; Burris HA; Wang B; Dees EC; Cortes J; Joshi A; Gupta M; Yi JH; Chu YW; Shih T; Fang L; Girish S
Curr Drug Metab; 2012 Sep; 13(7):911-22. PubMed ID: 22475266
[TBL] [Abstract][Full Text] [Related]
16. Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment.
Vilela MD; Longstreth WT; Pedrosa HAS; Gil GOB; Duarte JM; Filho MAD
World Neurosurg; 2018 Mar; 111():109-114. PubMed ID: 29274446
[TBL] [Abstract][Full Text] [Related]
17. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
Miller KD; Diéras V; Harbeck N; Andre F; Mahtani RL; Gianni L; Albain KS; Crivellari D; Fang L; Michelson G; de Haas SL; Burris HA
J Clin Oncol; 2014 May; 32(14):1437-44. PubMed ID: 24733796
[TBL] [Abstract][Full Text] [Related]
18. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab emtansine in breast cancer.
Dirix LY; Rutten A; Huget P; Dirix M
Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731
[TBL] [Abstract][Full Text] [Related]
20. Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.
Russillo M; Ferretti G; Vidiri A; Gasparro S; Cognetti F; Pellegrini D; Fabi A
In Vivo; 2018; 32(4):839-842. PubMed ID: 29936468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]